2009 - Fellow of the Indian National Academy of Engineering (INAE)
Surgery, Arthroplasty, Pathology, Bone morphogenetic protein and Bone morphogenetic protein 2 are his primary areas of study. Surgery is closely attributed to Anesthesia in his study. His Arthroplasty study incorporates themes from Chemoprophylaxis, Randomized controlled trial and Etiology.
The various areas that Jay R. Lieberman examines in his Pathology study include Patella, Bone morphogenetic protein 7, Cartilage and Osteoblast. His work carried out in the field of Bone morphogenetic protein brings together such families of science as Femur and Mesenchymal stem cell. His Bone morphogenetic protein 2 research is multidisciplinary, relying on both Stromal cell, Molecular biology, Genetic enhancement, Cell biology and Bone morphogenetic protein 5.
Jay R. Lieberman mostly deals with Surgery, Arthroplasty, Pathology, Bone healing and Genetic enhancement. His Surgery and Orthopedic surgery, Pulmonary embolism, Total hip arthroplasty, Complication and Femoral head investigations all form part of his Surgery research activities. His research investigates the connection between Arthroplasty and topics such as Physical therapy that intersect with problems in Joint arthroplasty and Total knee arthroplasty.
His Pathology study combines topics from a wide range of disciplines, such as Bone metastasis, Prostate cancer and Noggin, Bone morphogenetic protein. The Bone morphogenetic protein study combines topics in areas such as Bone morphogenetic protein 2 and Spinal fusion. His Genetic enhancement research includes elements of Tissue engineering, Ex vivo, Bioinformatics, Viral vector and Bone regeneration.
The scientist’s investigation covers issues in Arthroplasty, Genetic enhancement, Physical therapy, Bone healing and Total hip arthroplasty. His research integrates issues of Odds ratio, Orthopedic surgery, Depression and General surgery in his study of Arthroplasty. His Genetic enhancement research includes themes of Tissue engineering, Ex vivo, Cancer research, Viral vector and Bone regeneration.
Jay R. Lieberman works mostly in the field of Cancer research, limiting it down to topics relating to Umbilical cord and, in certain cases, Bone morphogenetic protein 2. Jay R. Lieberman interconnects Stem cell and Pathology in the investigation of issues within Bone healing. His Pathology study integrates concerns from other disciplines, such as Adipose tissue and Growth factor.
His primary areas of study are Arthroplasty, Surgery, Total hip arthroplasty, Physical therapy and Bone morphogenetic protein 2. In the field of Arthroplasty, his study on Total knee overlaps with subjects such as Joint replacement registry. His research in Surgery intersects with topics in Meta-analysis and Confidence interval.
His study looks at the intersection of Total hip arthroplasty and topics like Current Procedural Terminology with Orthopedic surgery. The concepts of his Physical therapy study are interwoven with issues in Total knee arthroplasty, Medicaid and Medicare reimbursement. In his study, which falls under the umbrella issue of Bone morphogenetic protein 2, Bone healing is strongly linked to Genetic enhancement.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Michael R. Lassen;Walter Ageno;Lars C. Borris;Jay R. Lieberman.
The New England Journal of Medicine (2008)
The role of growth factors in the repair of bone. Biology and clinical applications.
Jay R. Lieberman;Aaron Daluiski;Thomas A. Einhorn.
Journal of Bone and Joint Surgery, American Volume (2002)
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Jeffrey S Ginsberg;Bruce L Davidson.
Journal of Arthroplasty (2009)
The Effect of Regional Gene Therapy with Bone Morphogenetic Protein-2-Producing Bone-Marrow Cells on the Repair of Segmental Femoral Defects in Rats*
Jay R. Lieberman;Aaron Daluiski;Sharon Stevenson;La Jolla.
Journal of Bone and Joint Surgery, American Volume (1999)
Healing of Critically Sized Femoral Defects, Using Genetically Modified Mesenchymal Stem Cells from Human Adipose Tissue
Brett Peterson;Jeffrey Zhang;Roberto Iglesias;Michael Kabo.
Tissue Engineering (2005)
Bone induction by BMP-2 transduced stem cells derived from human fat
Jason L. Dragoo;Joon Y. Choi;Jay R. Lieberman;Jerry Huang.
Journal of Orthopaedic Research (2003)
Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads.
J. L. Dragoo;B. Samimi;M. Zhu;S. L. Hame.
Journal of Bone and Joint Surgery-british Volume (2003)
Minimally invasive total hip arthroplasty development, early results, and a critical analysis
Daniel J. Berry;Richard A. Berger;John J. Callaghan;Lawrence D. Dorr.
Journal of Bone and Joint Surgery, American Volume (2003)
Regional gene therapy with a BMP‐2‐producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents
Jay R. Lieberman;Lu Q. Le;Lilly Wu;Gerald A. M. Finerman.
Journal of Orthopaedic Research (1998)
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Charles W. Francis;Scott D. Berkowitz;Jay R. Lieberman.
The New England Journal of Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: